List of tables

Table 1: Patents on piperine (1996 - 2001)
Table 2: In-vitro and in-vivo effects of piperine on liver drug metabolising enzymes
Table 3: Melting points of isolated/synthesised compounds
Table 4: Absorbance data of animals sacrificed immediately after administration of phenol red (standard control)
Table 5: Effect of piperine (single dose and multiple dose) and its metabolites (single dose) on GE of phenol red in rats
Table 6: Effect of piperine (single dose and multiple dose) and its metabolites (single dose) on GE of spheroids in rats
Table 7: Effect of piperine (single dose and multiple dose) and its metabolites (single dose) on gastrointestinal transit in mice (charcoal meal)
Table 8: Concentration versus area for construction of calibration plot for piperine
Table 9: Recovery of piperine from rat plasma using 2 ml ethyl acetate with different extraction timings
Table 10: Recovery of piperine from rat plasma using 3 ml ethyl acetate with different extraction timings
Table 11: Recovery of piperine from rat plasma using 4 ml ethyl acetate with different extraction timings
Table 12: Intra and inter-assay variation for piperine
Table 13: Plasma concentrations of piperine in rats after its administration as suspension (170 mg/kg p.o.)
Table 14: Plasma concentrations of piperine in rats after its administration as solution (10 mg/kg p.o.)
Table 15: Plasma concentrations of piperine in rats after its administration as solution (20 mg/kg p.o.)
Table 16: Pharmacokinetic parameters of piperine
Table 17: Concentration versus area for construction of calibration plot for 5-fluorouracil
Table 18: Recovery of 5-FU from rat plasma using 2 ml ethyl acetate with different extraction timings
Table 19: Recovery of 5-FU from rat plasma using 3 ml ethyl acetate with different extraction timings
Table 20: Recovery of 5-FU from rat plasma using 4 ml ethyl acetate with different extraction timings
Table 21: Intra and inter-assay variation for 5-FU
Table 22: Concentration versus area for construction of calibration plot for AZT in plasma
Table 23: Recovery of AZT from rat plasma
Table 24: Intra and inter-assay variation for AZT
Table 25: Concentration versus area for construction of calibration plot for cefixime in plasma
Table 26: Concentration versus area for construction of calibration plot for cefixime in urine
Table 27: Concentration versus area for construction of calibration plot for cefixime in bile
Table 28: Intra and inter-assay variation for cefixime in different matrices
Table 29: Plasma concentrations of 5-FU in rats after administration of formulation FU (single dose study)
Table 30: Plasma concentrations of 5-FU in rats after administration of formulation FUP (single dose study)
Table 31: Plasma concentrations of 5-FU in rats after administration of formulation FUPNAL (single dose study)
Table 32: Plasma concentrations of 5-FU in rats after administration of formulation FUPA (single dose study)
Table 33: Plasma concentrations of 5-FU in rats after administration of formulation FU (multiple dose study)
Table 34: Plasma concentrations of 5-FU in rats after administration of formulation FUP (multiple dose study)
Table 35: Plasma concentrations of 5-FU in rats after administration of formulation FUPNAL (multiple dose study)
Table 36: Plasma concentrations of 5-FU in rats after administration of formulation FUPA (multiple dose study)
Table 37: Mean plasma 5-FU concentrations in rats after single and multiple dose studies
Table 38: Pharmacokinetic parameters of 5-FU (25 mg/kg p.o.) alone and in presence of piperine or its metabolites (single dose study)
Table 39: Pharmacokinetic parameters of 5-FU (25 mg/kg p.o.) alone and in presence of piperine or its metabolites (multiple dose study)
Table 40: Plasma concentrations of AZT in normal rats after administration of formulation AZ (single dose study)
Table 41: Plasma concentrations of AZT in normal rats after administration of formulation AZP (single dose study)
Table 42: Plasma concentrations of AZT in normal rats after administration of formulation AZPNAL (single dose study)
Table 43: Plasma concentrations of AZT in normal rats after administration of formulation AZPA (single dose study)
Table 44: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZ (single dose study)
Table 45: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZP (single dose study)
Table 46: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZPNAL (single dose study)
Table 47: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZPA (single dose study)
Table 48: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZ (multiple dose study)
Table 49: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZP (multiple dose study)
Table 50: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZPNAL (multiple dose study)
Table 51: Plasma concentrations of AZT in phenobarbital treated rats after administration of formulation AZPA (multiple dose study)
Table 52: Mean plasma AZT concentrations in rats after single and multiple dose studies
Table 53: Pharmacokinetic parameters of AZT (5 mg/kg p.o.) alone and in presence of piperine or its metabolites (normal rats)
Table 54: Pharmacokinetic parameters of AZT (5 mg/kg p.o.) alone and in presence of piperine or its metabolites (phenobarbital treated rats, single dose)
Table 55: Pharmacokinetic parameters of AZT (5 mg/kg p.o.) alone and in presence of piperine or its metabolites (phenobarbital treated rats, multiple dose)
Table 56: Plasma concentrations of cefixime in rats after administration of formulation CF (single dose study)
Table 57: Plasma concentrations of cefixime in rats after administration of formulation CFP (single dose study)
Table 58: Plasma concentrations of cefixime in rats after administration of formulation CFPNAL (single dose study)
Table 59: Plasma concentrations of cefixime in rats after administration of formulation CFPA (single dose study)
Table 60: Plasma concentrations of cefixime in rats after administration of formulation CF (pretreatment)
Table 61: Plasma concentrations of cefixime in rats after administration of formulation CFP (pretreatment)
Table 62: Plasma concentrations of cefixime in rats after administration of formulation CFPNAL (pretreatment)
Table 63: Plasma concentrations of cefixime in rats after administration of formulation CFPA (pretreatment)
Table 64: Plasma concentrations of cefixime in rats after administration of formulation CF (multiple dose study)
Table 65: Plasma concentrations of cefixime in rats after administration of formulation CFP (multiple dose study)
Table 66: Plasma concentrations of cefixime in rats after administration of formulation CFPNAL (multiple dose study)
Table 67: Plasma concentrations of cefixime in rats after administration of formulation CFPA (multiple dose study)
Table 68: Mean plasma cefixime concentrations in rats after single dose, pretreatment and multiple dose studies
Table 69: Pharmacokinetic parameters of cefixime (25 mg/kg p.o.) alone and in presence of piperine or its metabolites (single dose study)
Table 70: Pharmacokinetic parameters of cefixime (25 mg/kg p.o.) alone and in presence of piperine or its metabolites (pretreatment)
Table 71: Pharmacokinetic parameters of cefixime (25 mg/kg p.o.) alone and in presence of piperine or its metabolites (multiple dose study)
Table 72: Urinary excretion of cefixime (25 mg/kg p.o.) alone and in presence of piperine or its metabolites (single and multiple dose studies)
Table 73: Biliary excretion of cefixime (25 mg/kg p.o.) alone and in presence of piperine or its metabolites (single and multiple dose studies)
Table 74: Comparative in-vitro cytotoxicity of 5-FU alone and in combination with piperine
Table 75: Mean plasma cefixime concentrations in rats after single and multiple dose studies